Showing 2,841 - 2,860 results of 3,491 for search '"Stem Cell"', query time: 0.08s Refine Results
  1. 2841
  2. 2842

    Electroacupuncture-Regulated miR-34a-3p/PDCD6 Axis Promotes Post-Spinal Cord Injury Recovery in Both In Vitro and In Vivo Settings by Lili Ma, Lizhong Ma, Yu Yang, Ting Chen, Limin Wang, Qilong Deng

    Published 2022-01-01
    “…Our in vitro results showed that miR-34a-3p might promote the in vitro differentiation of neural stem cell (NSC) through suppressing PDCD6 and regulating other important neural markers such as fibroblast growth factor receptor 1 (FGFR1), MAP1/2 (MAP kinase kinases 1/2), myelin basic protein (MBP), βIII-tubulin Class III β-tubulin (βIII tubulin), and glial fibrillary acidic protein (GFAP). …”
    Get full text
    Article
  3. 2843

    Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication by Dohoon Lee, Bonil Koo, Seokhyeon Kim, Jamin Byun, Junshik Hong, Dong-Yeop Shin, Choong-Hyun Sun, Jaesung Kim, Ji-Joon Song, Siddhartha Jaiswal, Sung-Soo Yoon, Sun Kim, Youngil Koh

    Published 2025-01-01
    “…This epigenetic heterogeneity was associated with the transcriptional variability of developmental and membrane-associated factors shaping stem cell niche, and also was a predictor of the response of AML cells to hypomethylating agents, implying that the survival of AML cells depends on stochastic DNA methylations at bivalent domains. …”
    Get full text
    Article
  4. 2844
  5. 2845

    Macular Changes in a Mucopolysaccharidosis Type I Patient with Earlier Systemic Therapies by Augusto Magalhães, Ana Maria Cunha, Rodrigo Vilares-Morgado, Elisa Leão-Teles, Esmeralda Rodrigues, Manuel Falcão, Ângela Carneiro, Jorge Breda, Fernando Falcão-Reis

    Published 2021-01-01
    “…To describe retinal findings in a patient with mucopolysaccharidosis type I (MPS I) that underwent an early treatment with hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). …”
    Get full text
    Article
  6. 2846

    Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation by Michela Staderini, Lara Mannelli, Elisabetta Antonioli, Benedetta Puccini, Valentina Berti, Francesco Mungai, Federica Vergoni, Valentina Carrai, Luigi Rigacci, Alberto Bosi

    Published 2020-01-01
    “…The therapeutic program initially included chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CHOEP), radiotherapy on the leg, bortezomib, and then consolidation with autologous hematopoietic stem cell transplantation. Despite being on bortezomib treatment and waiting for transplantation, the patient experienced an early myeloma progression that turned out to be refractory to second-line lenalidomide-based treatment. …”
    Get full text
    Article
  7. 2847

    Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis by Timothy F Platts-Mills, Christopher W Jones, Ashley L Woodford

    Published 2020-09-01
    “…There are also at least 25 registered trials of azithromycin (n=53), convalescent plasma (n=38), lopinavir/ritonavir (n=30), stem cell treatments (n=29) and tocilizumab (n=25). 142 trials were registered in the first 3 months of 2020, and 488 trials were registered between 1 April and 1 May 2020.Conclusions These findings demonstrate a robust research response to the COVID-19 pandemic, though many of the currently planned and ongoing trials focus on a small number of potential therapies, and many also lack essential design features and power necessary to provide accurate treatment effect estimates.…”
    Get full text
    Article
  8. 2848

    Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. by Ann Mari Rosager, Mia D Sørensen, Rikke H Dahlrot, Steinbjørn Hansen, David L Schonberg, Jeremy N Rich, Justin D Lathia, Bjarne W Kristensen

    Published 2017-01-01
    “…Double-immunofluorescence showed that TfR1, FTH, and FTL were co-expressed to a limited extent with the stem cell-related marker CD133. FTH and FTL were also co-expressed by IBA-1-positive microglia/macrophages. …”
    Get full text
    Article
  9. 2849
  10. 2850
  11. 2851
  12. 2852
  13. 2853
  14. 2854

    Histopathological and Immunohistochemical Evaluation of Methotrexate-Induced Gonadal Damage in Rats: Role of SCF, mTOR, and SIRT-1 by Kübra Tuğçe KALKAN, Betül YALÇIN, Özge CENGİZ MAT, Arzu Hanım YAY

    Published 2024-12-01
    “…In addition, the immunoreactivity intensities of stem cell factor (SCF), mechanistic target of rapamycin (mTOR), and SIRT-1 in both tissues were measured by immunohistochemistry. …”
    Get full text
    Article
  15. 2855
  16. 2856

    CCN3: lactational bone booster by Nathan Xu, Kyle Yang, Mengjie Wang

    Published 2024-12-01
    “…Compelling evidence has been presented to show that (1) CCN3 expression in ARHERα/Kiss1 neurons fluctuates, almost exclusively appearing during lactation; (2) CCN3 stimulates mouse and human skeletal stem cell activity, increases bone remodeling and fracture repair in young and old mice of both sexes; (3) knockdown Ccn3 transcripts in the ARHKiss1 neurons in lactating dams causes devastating bone loss and failure to sustain progeny survival. …”
    Get full text
    Article
  17. 2857
  18. 2858

    Renal Transplantation in Hepatitis C Positive Patients: A Single Centre Experience by P. R. Shah, A. V. Vanikar, M. R. Gumber, H. V. Patel, V. B. Kute, S. M. Godara, H. L. Trivedi

    Published 2011-01-01
    “…TIP consisted of 1 donor-specific transfusion, peripheral blood stem cell infusion, portal infusion of bone marrow, and target-specific irradiation. …”
    Get full text
    Article
  19. 2859
  20. 2860